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Defective Iron Supply for Erythropoiesis and Adequate Endogenous 
Erythropoietin Production in the Anemia Associated With Systemic-Onset 
Juvenile Chronic Arthritis 
By Mario Cazzola, Luisa Ponchio, Fabrizio de Benedetti, Angelo Ravelli, Vittorio Rosti, Yves Beguin, 
Rosangela Invernizzi, Giovanni Barosi, and Albert0 Martini 
Systemic-onset juvenile chronic arthritis (SoJCA) is associ- 
ated with high levels of circulating interleukin-6 (11-6) and is 
frequently complicated by severe microcytic anemia whose 
pathogenesis is unclear. Therefore, we studied 20 consecu- 
tive SoJCA patients with hemoglobin (Hb) levels e12 g/dL, 
evaluating erythroid progenitor proliferation, endogenous 
erythropoietin production, body iron status, and iron supply 
for erythropoiesis. Hb concentrations ranged from 6.5 to 11.9 
g/dL. Hb level was directly related to mean corpuscular vol- 
ume ( r  = .82, P e .001) and inversely related to circulating 
transferrin receptor ( r  = -81. P e .001), suggesting that the 
severity of anemia was directly proportional to the degree 
of iron-deficient erythropoiesis. Serum ferritin ranged from 
18 to 1,660 pg/L and was unrelated to Hb level. Bone marrow 
iron stores were markedly reduced in the three children in- 
vestigated, and they also showed increased serum trans- 
ferrin receptor and normal-to-high serum ferritin. All 20 pa- 
tients had elevated IL-6 levels and normal in vitro growth 
of erythroid progenitors. Endogenous erythropoietin (epo) 
production was appropriate for the degree of anemia as 
judged by both the observed to predicted log (serum epo) 
ratio (0.95 f 0.12) and a comparison of the serum epo-Hb 
regression found in these subjects with that of thalassemia 
NEMIA ASSOCIATED with rheumatoid arthritis is con- A sidered the prototype of anemia of inflammation; its 
pathogenesis is multifactorial and cytokines appear to play 
a crucial role.’ Tumor necrosis factor-a (TNF-a) and in- 
terleukin-1 (IL-1), whose levels are increased in active rheu- 
matoid arthritis,’ inhibit erythroid progenitor 
and may blunt erythropoietin (epo) response to anemia! 
These cytokines are also responsible for the alterations in 
iron metabolism that result in reduced iron supply to the 
erythroid marrow.’ An impaired epo response to anemia has 
been shown in adult patients with active rheumatoid arthri- 
and recombinant human epo has been found to be 
effective in ameliorating anemia in patients with active dis- 
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patients. Multiple regression analysis showed that serum 
transferrin receptor was the parameter most closely related 
to hemoglobin concentration: variation in circulating trans- 
ferrin receptor explained 61% of the variation in Hb level (Pe 
.0011. In 10 severely anemic patients, amelioration of anemia 
following intravenous iron administration resutted in nor- 
malization of serum transferrin receptor. Defective iron sup- 
ply to the erythron rather than blunted epo production is 
the major cause of the microcytic anemia associated with 
SoJCA. A true body-iron deficiency caused by decreased iron 
absorption likely complicates long-lasting inflammation in 
the most anemic children, and this can be recognized by 
high serum transferrin receptor levels. Although oral iron is 
of no benefit, intravenous iron saccharate is a safe and effec- 
tive means for improving iron availability for erythropoiesis 
and correcting this anemia. Thus, while chronically high en- 
dogenous IL-6 levels do not appear to blunt epo production, 
they are probably responsible for the observed abnormali- 
ties in iron metabolism. Anemia of chronic disease encom- 
passes a variety of anemic conditions whose peculiar fea- 
tures may specifically correlate with the type of cytokine(s) 
predominantly released. 
0 7996 by The American Society of Hematology. 
(SoJCA) frequently develop severe microcytic anemia.I3 The 
extreme microcytosis of these young patients indicates that 
markedly impaired iron supply to the erythroid marrow may 
be a major pathogenetic mechanism.I4 Some of the investiga- 
tors had previously found a strong correlation between serum 
IL-6 levels and joint involvement and thrombocytosis in 
SoJCA, suggesting that IL-6 may play a significant role in 
the pathogenesis of this It is presently unclear 
whether IL-6 is also involved in the pathogenesis of anemia. 
In the present work, we studied the mechanisms of anemia 
in 20 consecutive anemic children with SoJCA by evaluating 
endogenous epo production, erythroid marrow proliferation, 
body-iron status, and adequacy of iron supply to the ery- 
throid marrow.” In a companion report,’* we have already 
shown that intravenous (IV) iron administration can be effec- 
tive in correcting severe long-lasting anemia associated with 
SoJCA. 
MATERIALS AND METHODS 
Patients and study design. All consecutive patients observed at 
the Department of Pediatrics of the IRCCS Policlinico S .  Matteo 
Hospital between April 1991 and June 1994 who fulfilled the criteria 
for a diagnosis of S O J C A ’ ~ . ~  were considered for the study. Informed 
consent was obtained from the parents. Follow-up studies were con- 
tinued until November 1994. 
This study was originally designed to identify the mechanism(s) 
of anemia in individual patients with SoJCA and to provide them 
with the most appropriate treatment. Therapeutic options included: 
(I)  oral iron; (2) IV iron; (3) administration of recombinant human 
epo (rHuEpo). Oral iron was planned as a first-line treatment; nonre- 
sponders were then to be moved to IV iron. If a response was still 
not achieved and there was evidence of blunted endogenous epo 
4824 Blood, Vol 87, No 11 (June 1). 1996: pp 4824-4830 
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production, rHuEpo administration was considered as the final thera- 
peutic option. 
To be included in the study patients had to display hemoglobin 
(Hb) levels < 12 g/dL in two consecutive samples drawn more than 
3 months apart, be available for regular follow-up during the study, 
have normal vitamin B12 and folate serum levels, and show no 
evidence of a- or P-thalassemia trait. No investigation for thalas- 
semia was performed in children with at least one normal mean 
corpuscular volume (MCV) value in previous testing. Quantitation 
of Hb Az in the patient and blood cell counts in the parents were 
routinely performed in cases showing exclusively low MCV values. 
Twenty SoJCA patients met the above criteria: 13 males and 7 
females with a median age of 7.7 years (range, 1.5 to 17.5). These 
20 subjects included the 8 children previously reported in the com- 
panion report." All patients were treated with nonsteroidal anti- 
inflammatory drugs; 9 were given low-dose weekly methotrexate and 
11 received low-dose prednisone. None of the participants showed 
evidence of blood loss as evaluated by three consecutive Hemoccult 
tests of stools. Disease activity was assessed by measuring West- 
ergren erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP), and by counting the number of active joints. 
After a preliminary work-up only the 17 patients showing Hb 
levels < 10 g/dL were considered suitable for treatment. These sub- 
jects were first treated with vials of oral iron (ferrous sulphate) at a 
dose of 3 mg/kg/d for 8 weeks. Two children discontinued iron after 
a few days so that only 15 were evaluable. Fourteen of these 15 
showed an increase in Hb level <1 g/dL at the end of this period 
and were considered unresponsive to oral iron; the remaining child 
showed an Hb increase of 1.2 g/dL. 
The next therapeutic option, ie, IV iron therapy (iron oxide saccha- 
rate, Fe r "  Hausman; Laboratorien Hausman, St Gallen, Switzer- 
land) was offered to the 14 children unresponsive to oral iron and 
discussed with their parents in each case. Informed consent was 
obtained for 11 children. One of these patients was subsequently 
lost at follow-up so that 10 participants were available for the effi- 
cacy studies of IV iron administration, including the 8 previously 
reported children." From a mean post-oral iron value of 8.0 5 0.8 
g/dL, Hb levels increased to 1 1.5 % 0.9 g/dL after IV iron administra- 
tion (P < ,001). This amelioration of anemia and the results of 
studies on endogenous epo production reported below made the 
prospective use of rHuEpo unnecessary. 
Hematological projile and iron status. Blood counts were deter- 
mined with a Coulter Counter Model S (Coulter, Hialeah, FL). Retic- 
ulocyte counts were performed by microscopic observation after 
staining with brillant cresyl blue and corrected to account for ane- 
mia?' A corrected reticulocyte count more than three times basal 
level in an anemic patient is taken to indicate adequate red blood 
cell production (ie, peripheral hemolysis), whereas an index of less 
than three times basal is assumed to represent impaired red blood 
cell production.2' 
Body-iron status was evaluated by measuring serum iron, total 
iron-binding capacity, and serum femtin. This latter was determined 
with a radioimmunoassay method (Ramco Lab, Houston, TX). Prus- 
sian blue staining of marrow iron was performed as previously de- 
tailed" to evaluate both iron deposition in individual erythroblasts 
and reticuloendothelial iron stores. The positivity of erythroblasts 
was scored on each bone marrow (BM) specimen using the following 
criteria: 0, no stainable granules; 1+, 1 or 2 stainable granules; 2+, 
3-5 stainable granules; 3+, >5 stainable granules. The positivity 
of reticuloendothelial cells was scored using the following criteria: 0, 
no reactivity; 1 +, a few slightly positive cells or a few extracellular 
granules; 2+, some positive cells; 3+, numerous positive cells; 4+, 
massive positivity. 
Circulating epo levels were measured by a 
commercially available radioimmunoassay (Incstar Corp, Stillwater, 
Serum epo assay. 
MN) that uses recombinant human epo for tracer and ~tandards.2~ 
To define epo levels as appropriate or inappropriate for a given 
degree of anemia, an exponential regression of serum epo versus 
hematocrit (Hct) was determined in reference subjects (102 normal 
individuals or patients with iron deficiency anemia, hemolytic ane- 
mia, or hypoplastic anemia), and the 95% confidence limits were 
defined.23 For Hct values s40%, the regression equation was: 
log(epo) = 3.42 - (0.056 X Hct). For Hct values >40%, theregres- 
sion equation was: log(ep0) = 1.31 - (0.003 X Hct). Based on 
these equations, the observedlpredicted log(epo) ratio (OF ratio) 
was derived for each sample. The mean O F  ratio in reference sub- 
jects was 1.01 ? 0.11 (95% confidence interval: 0.80-1.22). 
Growth of erythroid 
progenitors from peripheral blood (PB) mononuclear cells was as- 
sayed as previously described in detail." Light-density mononuclear 
cells were separated from PB by centrifugation on a Ficoll-Hypaque 
gradient (Pharmacia Biotech, Uppsala, Sweden) (density 1.077 g/ 
mL) at 4aOg for 40 minutes at 20°C. Interface cells were washed 
and suspended in Iscove's modified Dulbecco's medium (IMDM; 
Seromed, Berlin, Germany). Briefly, 5 X lo5 mononuclear cells were 
plated in 35-mm Petri dishes in 1-mL aliquots of IMDM containing 
30% fetal bovine serum (HyClone, Logan, UT), 5 X m o m  2- 
mercaptoethanol, 2 IU of epo, and 0.9% (wt/vol) methylcellulose. 
Assays were performed in duplicate. After incubation for 14 days 
at 37°C in a fully humidified atmosphere supplemented with 5% 
CO2, the number of colonies was scored using an inverted micro- 
scope. Burst-forming units-erythroid (BFU-E) were defined as bursts 
of 3 or more hemoglobinized subcolonies consisting of at least 200 
erythroid cells. 
The total number of mononuclear cells obtained per unit volume 
of PB after separation on a Ficoll-Hypaque gradient was calculated 
to serve as a basis for the determination of the number of bursts 
grown per unit volume of PB. The following formula was used: 
Circulating erythroid progenitor assay. 
BFU-E - BFU-E Mononuclear CeIldmL 
mL Dish No. of Mononuclear Cells Plated 
Measurement of serum transferrin receptor (TfR). The amount 
of circulating TfR was estimated by an enzyme-linked polyclonal 
antibody assay, using purified placental receptor-transferrin com- 
plexes as a reference standard and rabbit antibodies as described in 
detail el~ewhere.'~ The mean serum TfR level in 165 normal control 
subjects was 5.0 5 1.1 mgL, with 95% confidence limits ranging 
from 2.9 to 7.1 mgk.  
Serum IL-6 assay. Serum IL-6 levels were measured using the 
hybridoma cell line B9 (kindly provided by Dr L. Aarden, Nether- 
lands Red Cross, Amsterdam), as described in detail elsewhere.'5,25 
Chinese hamster ovary cell-derived recombinant human IL-6 (Gen- 
zyme Corp, Boston, MA) was used to culture B9 cells and as a 
standard in the assay. IL-6 was expressed as picograms per milliliter. 
To define a normal reference population, 
we selected 30 normal children well matched with respect to sex 
and age. 
Evaluation of the adequacy of endogenous epo production relies 
primarily on comparison with reference patients. This was performed 
by using two different approaches. First, the observedlpredicted 
log(epo) ratio (OF ratio) was calculated in each patient as described 
above. Second, we compared the serum epo-Hb regression found in 
SoJCA patients with that observed in 20 patients with &thalassemia 
intermedia. 
Data were stored, analyzed, and 
reported with the packages STATISTICAMac (Statsoft, Tulsa, 
OK), Exstatix (Select Micro Systems Inc, Yorktown Heights, NY) 
and DeltaGraph Pro 3 (DeltaPoint Inc, Monterey, CA), all run on a 
Macintosh Quadra 650 (Apple Computer Inc, Cupertino, CA) per- 
Reference populations. 
Data analysis andpresentation. 
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Table 1. Hematologic and Iron Status Parameters in 20 Patients With SoJCA and in a Normal Control Population 
ANOVA (F test) Patients (n  = 20) Reference Values ( n  = 30) 
Hb, g/dL 8.9 +- 1.4 (6.5-11.9) 13.2 +- 1.3 (11.4-15.5) P <  ,001 
MCV, FL 66 t 7 (55-77) 82 t 3 (77-89) P <  ,001 
Serum iron, pg/dL 18 2 12 (5-47) 83 +- 22 (57-135) P <  ,001 
Transferrin saturation, % 6 -t 4 (2-17) 25 t 6 (16-38) P i  .001 
Serum transferrin receptor, mg/L 14.4 t 9.7 (5.0-41.5) 5.4 5 1.7 (2.6-9.9) P i ,001 
Serum erythropoietin, mU/mL 65 2 60 (18-221) 17 t 6 (8-35) P i  ,001 
Serum ferritin, pg/dL 278 t 416 (18-1660) 41 2 15 (18-76) P = ,004 
Erythropoietin O/P ratio 0.95 2 0.12 (0.76-1.18) 0.96 t 0.10 (0.76-1.16) P = .80 
Circulating BFU-E, no./mL* 225 2 90 (95-365) 237 +- 72 (88-321) P =  .64 
Reference values were obtained in 30 normal subjects matched for sex and age. Data are expressed as mean 2 1 SD with range in parentheses. 
* BFU-E were studied in 20/30 reference subjects. 
sonal computer. Results were expressed as mean 2 1 SD unless 
otherwise stated. Simple and multiple linear regression, and nonlin- 
ear regression analysis were used to identify the parameters most 
closely related to Hb. The Student’s t-test andor the F test (one- 
way analysis of variance) were used to evaluate the probability of 
significant differences between groups. P values less than .05 were 
considered statistically significant. 
RESULTS 
Red blood cell counts and body iron status. The hemato- 
logic parameters of the 20 SoJCA patients are compared 
with those of normal controls in Table 1. Hb levels ranged 
from 6.5 to 11.9 g/dL and the anemia was microcytic in all 
the examined children, with MCV varying from 55 to 77 
fL. As shown in Fig 1, there was a direct relationship be- 
tween Hb and MCV ( r  = 32,  P < ,0001). The corrected 
reticulocyte count ranged from 0.7% to 2.6% and was unre- 
lated to Hb level, indicating impaired red blood cell produc- 
tion. 
Iron and transferrin saturation were markedly reduced in 
all children, whereas serum ferritin levels were normal or 
elevated, extending from 18 to 1,660 pg/L (Table 1). Al- 
though there was no relationship between Hb and serum 
ferritin, this latter parameter was directly related to ESR ( r  
= .50, P < .05). In addition, patients with ESR values > 
80 “AI had higher femtin levels than those of patients 
with ESR values 5 80 “AI (Table 2). 
A “t- 
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Fig 1. Relationship between Hb level and MCV (A) and serum TfR 
IS). 
Previous studies have recommended adjusted serum ferri- 
tin cutoffs of 60 to 70 p g n  for defining iron depletion in 
patients with concomitant i n f l a m m a t i ~ n . ~ ~ . ~ ~  We used two 
cutoffs, 60 pg/L and the median value of 133 pg/L, to divide 
patients into subgroups and to identify any significant differ- 
ences (Table 2). Patients with femtin levels <60 pg/L had 
lower MCV ( P  < .05) but their Hb values did not differ 
significantly from those of patients with serum ferritin 260  
pg/L. Using a cutoff of 70 pg/L yielded identical results, 
whereas a cutoff of 133 pg/L (median value) was useless. 
Circulating serum TfR levels ranged from 5.0 to 41.5 mg/ 
L. As shown in Fig 1, there was an inverse exponential 
relationship between this parameter and Hb level ( r  = -.8 1, 
P < .0001). Using the median value for serum TfR of 10.4 
mg/L, SoJCA patients were split into two groups with sig- 
nificantly different Hb and MCV values (Table 2). Using 
the upper normal limit of 7.1 mg/dL would have resulted in 
two extremely unequal subgroups (4 v 16 subjects). 
Following parents’ consent, BM examination was per- 
formed in three children whose Hb ranged from 6.7 to 7.8 
g/dL in order to decide whether to proceed to IV iron. As 
shown in Table 3, none of the three children showed stain- 
able iron in the erythroblasts and all presented markedly 
reduced reticuloendothelial iron stores; serum ferritin was 
normal to high, whereas serum TfR was clearly elevated. 
This pattern was consistent with a combination of iron defi- 
ciency and inflammation. A previous study on  adult patients 
with Still’s disease, ie, the adult counterpart of SOJCA,” 
also showed a reduction in erythroblastic iron but normal 
to increased nonerythroblastic iron with markedly elevated 
serum ferritin, as typically found in inflammation. 
The severity of anemia was not correlated 
with disease activity, as judged by ESR or by the number of 
active joints (data not shown). All patients showed increased 
serum levels of IL-6; the median value was 485 pg/mL 
(range, 49 to 1,476 pg/mL). In our laboratory, 95% of normal 
subjects have undetectable IL-6 levels and the remaining 5% 
show values from 5 to 18 ~g /mL. ’~  
Although there was no relationship between Hb and IL-6 
levels, linear regression analysis showed that IL-6 concentra- 
tion was directly related to platelet count ( r  = .64, P = 
,001). 
Endogenous epo production and erythroid proliferation. 
As shown in Table 1, all children had O/P ratio values within 
IL-6 levels. 
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Table 2. Comparison Between Patients Showing Values for ESR, Serum Ferritin, or Circulating 
Transferrin Receptor (TfR) < or z Defined Cutoffs 
Patients Hb, a/dL MCV, fL Transferrin Receptor, m g R  Serum Ferritin, pg/L 
All patients (n = 20) 8.9 i 1.4 66 f 7 14.4 2 9.7 278 f 416 
ESR 5 80 mm/h (n = 10) 
ESR > 80 mm/h (n = 10) 
9.0 f 1.5 
8.9 f 1.4 
65 ~t: 6
67 f 7 
NS NS 
61 f 3 
68 2 7 
Ferritin s 60 pg/L (n = 5) 
Ferritin > 60 bg/L (n = 15) 
8.1 f 1.2 
9.2 f 1.4 
NS P <  .05 
Ferritin 5 133 pg/L fn = 10) 8.6 i 1.2 65 f 6 
Ferritin > 133 pg/L (n = 10) 9.3 i 1.4 67 2 7 
NS NS 
15.0 -C 11.4 
13.7 2 8.2 
NS 
20.8 5 14.1 
12.2 ? 7.1 
NS 
15.2 i 11.2 
13.6 5 8.4 
NS 
107 5 98 
449 +. 540 
P <  .01 
TfR 5 10.4 mg/L (n = 10) 8.1 f 1.2 61 f 4 - 311 f 492 
TfR > 10.4 mg/L (n = 10) 9.7 f 1.0 71 f 6 - 244 2 349 
P <  .01 P < .001 NS 
80 mm/h is the median ESR value of the study population; 60 pg/L is the discriminant cutoff proposed by Hansen and Hansen" for the 
prediction of iron-responsive anemia in patients with rheumatoid arthritis, whereas 133 pg/L is the median ferritin concentration of the present 
patient population; 10.4 mg/L is the median TfR concentration. Comparison was performed by using one-way analysis of variance; values for 
serum ferritin were analyzed after log transformation. Pvalues are shown just below the pertinent means: NS = P > .05. 
the normal range, indicating that endogenous epo production 
was adequate for the degree of anemia. There was no rela- 
tionship between the OR' ratio and circulating TW, ESR, 
CRP, or IL-6 level. 
To further evaluate the adequacy of endogenous epo pro- 
duction, we compared the serum epo-Hb regression observed 
in patients with SoJCA to that obtained in a group of 20 
thalassemia intermedia patients. As shown in Fig 2, the re- 
gression curves did not differ significantly with respect to 
either slope or location, indicating that the two populations 
examined (SoJCA v thalassemia intermedia) were indistin- 
guishable regarding the regulation of epo production. 
In 6 children who were treated with IV iron saccharate 
and responded with amelioration or complete correction of 
anemia, serum epo was measured sequentially following iron 
administration. As illustrated in Fig 3, improvement in Hb 
concentration was associated with a proportional decrease 
in serum epo; all points fell within the previously defined 
95% confidence interval,23 indicating physiological regula- 
tion of endogenous epo production. 
Mean circulating BFU-E numbered 225 ? 90 per mL of 
blood, which was not significantly different from the mean 
normal value of 237 ? 72 (Table 1). There was no relation- 
ship between BFU-E counts and Hb level. 
Multiple regression analysis for identijication of factors 
injuencing Hb level. Multiple linear regression analysis 
was performed to study the relationship between Hb concen- 
tration and the following parameters: reticulocyte count, 
white blood cell (WBC) count, platelet (PLT) count, serum 
iron, serum ferritin, serum TW, ESR, IL-6, epo O/P ratio, 
circulating BFU-E. Serum TfR was found to be the one most 
closely related to Hb concentration: 61% of the variation in 
Hb level was explained by variations in serum TfR ( r  = 
-.78, P < .0001). Addition of serum iron and PLT count 
significantly increased the multiple correlation coefficient 
(multiple r )  to 0.88; the combination of serum TW, serum 
iron, and PLT count explained 74% of the variation in Hb 
concentration. 
Injuence of IV iron therapy on Hb level and circulating Tf l  
level. Ten patients received IV iron saccharate and all re- 
sponded with amelioration of anemia. As shown in Fig 4, this 
resulted in a progressive decrease in the circulating TfR level. 
Analysis of variance showed that changes in Hb level and serum 
TfR were sigruficantly different from zero (P < .001). 
DISCUSSION 
Juvenile chronic arthritis is a clinically heterogenous con- 
dition currently divided into different clinical forms based 
Table 3. EM Stainable Iron and Laboratory Parameters of Body-Iron Status in Three SoJCA Children 
BM Iron (Perl's) 
Erythroblastic, Nonerythroblastic, Serum Serum Transferrin, 
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Fig 2. Relationship of serum epo to Hb concentration in 20 SoJCA 
(0) patients and in 20 pthalassemia intermedia (0) patients. The 
exponential regression curves are shown (the upper one refers to 
SdCA, the lower one to thalassemia intermedia). Regression equa- 
tions were the following: In epo = 7.68 - 0.43 Hb ( r  = -.73, P < ,001) 
for SdCA, and In epo = 7.61 - 0.40 Hb ( r  = -BO, P < .001) for 
thalassemia intermedia patients. Univariate tests showed no signifi- 
cant difference between the two groups with respect to either Hb or 
serum epo. Multivariate tests (MANCOVA Wilks’ Lambda and Pillai- 
Bartlett Trace) showed no significant difference between the two 
regression curves with respect to either slope or location. 
on symptoms at The systemic form, or SoJCA, is 
characterized by chronic arthritis associated with high spik- 
ing fever, other systemic features and prominent laboratory 
evidence of inflammation. Because IL-6 plays an important 
role in the pathogenesis of SOJCA,’~.’~,’~ this condition may 
also be viewed as a model for studying the effect of excessive 
endogenous IL-6 production on erythropoiesis and iron me- 
tabolism. 
Severe microcytic anemia is found not only in children 
with SoJCA but also in adult patients with Still’s disease, 
in whom IL-6 production is increased,” and in mice trans- 
planted with hematopoietic cells constitutively expressing 
human IL-6.30 Therefore, IL-6 is an attractive candidate as 
a mediator of severe microcytic anemia in chronic arthritis. 
Theoretically, IL-6 may inhibit erythroid progenitor prolifer- 
ation, blunt epo production, or impair iron supply for erythro- 
poiesis. 
Available evidence argues against any inhibitory effect of 
IL-6 on erythroid progenitors. In fact, IL-6 does not impair 
CAZZOLA ET AL 
in vitro erythroid colony formation”’ whereas it can syner- 
gize with other hematopoietic growth factors to enhance 
hematop~iesis .~’ .~~ Results of the present study indicate that 
the number of circulating BFU-E in SoJCA patients is in the 
normal range in spite of elevated IL-6 levels. Similarly, in 
a recent phase 1-11 study on cancer patients, the number of 
BFU-E was not affected by 7 days of recombinant human 
IL-6 treatment, excluding any suppressive effect on in vivo 
erythr~poiesis.’~ 
An impaired epo response to anemia is believed to be 
typical of chronic disease.’ Faquin et a16 showed that several 
cytokines, including IL- 1, TNF-a, and TGF-P, inhibited 
hypoxia-induced epo production from the hepatoma cell line 
Hep3B. Interestingly, however, the addition of IL-6 to hyp- 
oxic Hep3B cells resulted in dose-dependent stimulation of 
hypoxia-induced epo production.6 In phase 1-11 clinical trials 
on IL-6 administration to cancer patients, epo levels in- 
creased in a dose-dependent manner and decreased after ces- 
sation of IL-6.34.35 In the present study, no patient displayed 
evidence of defective endogenous epo production, sug- 
gesting that this latter mechanism is not involved in the 
pathogenesis of the anemia associated with SoJCA. 
We believe that a large body of evidence points to the 
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Fig 3. Relationship between Hb level and serum epo in seven 
SdCA patients. These subjects were studied sequentially at different 
times as Hb level improved after IV iron therapy. 
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Fig 4. Time course of Hb, cir- 
culating TfR and serum ferritin 
after IV iron therapy in 10 SalCA 
patients. Symbols and bars are 
mean values * 1 SD (1 SEM for 
serum ferritin). Iron administra- 
tion produced a sharp increase 
in serum fewitin followed by a 
subsequent slow decrease. This 
latter result was paralleled by in- 
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production, including that of SoJCA, is mainly determined 
by a severe impairment of the iron supply to the developing 
erythroid cells. Administration of recombinant human IL-6 
to first provokes a rapid and reversible dilution 
anemia due to an increase in plasma volume; it also results 
in a rapid decrease in serum iron34335 and a tendency toward 
development of microcyt~sis.~~ However, because of the 
short exposure to IL-6 in this setting, hypoferremia is un- 
likely to considerably contribute to anemia. 
The question is different with SoJCA patients who are 
exposed to high levels of endogenous E - 6  for long periods 
of time. In the present study, serum TfR was the parameter 
most closely related to Hb concentration. The erythroid mar- 
row is the main source of soluble TfRs, and receptor density 
on erythroblasts increases as erythropoiesis becomes iron 
deficient; this in turn results in increased release of truncated 
receptors and elevated serum 1e~els . I~  Therefore, the above 
relationship indicates that the degree of iron-deficient eryth- 
ropoiesis is proportional to the severity of anemia. The utility 
of circulating TfR in diagnosing iron-deficient erythropoiesis 
in patients with active inflammatory processes has already 
been s h o ~ n . ~ ~ , ~ '  
The defective supply of iron to developing erythroid cells, 
responsible for the anemia associated with SoJCA, may be 
the consequence of both severe reticuloendothelial iron block 
and true iron deficiency. Harvey et all3 suggested that the 
former mechanism is probably operating in most cases of 
active SoJCA. In our opinion, disease duration is also rele- 
vant to the pathogenesis of anemia. SoJCA patients at clini- 
cal onset13 as well as adult patients with Still's disease" show 
the typical pattern of iron-deficient erythropoiesis caused by 
severe reticuloendothelial iron block. However, subjects with 
active rheumatoid arthritis have decreased iron absorption3' 
and our SoJCA patients with severe long-lasting anemia re- 
sponded to IV but not to oral iron treatment, suggesting iron 
malabsorption. Impaired iron absorption can easily result in 
iron deficiency in a growing child with physiologically low 
body-iron stores. Data reported in Table 3 suggest that, al- 
though some iron may be trapped in the reticuloendothelial 
cells, a true iron deficiency is probably present in the most 
anemic children with long-lasting active SoJCA. Nonethe- 
less, IV iron administration might not only correct iron defi- 
ciency but also overcome macrophage trapping to some ex- 
tent, thereby also improving erythroid iron supply in patients 
whose major mechanism of anemia is a reticuloendothelial 
iron 
Excessive production of IL-6 might be directly responsible 
for the observed abnormalities in iron metabolism. Studies 
in cellular and animal models indicate that this cytokine may 
enhance ferritin synthesis and increase hepatic uptake of 
serum i r ~ n . ~ ' , ~ '  In turn, increased ferritin expression results 
in reticuloendothelial iron block and impairs iron absorption. 
In conclusion, the chronic anemia associated with high 
IL-6 levels appears to be peculiar in that it is associated with 
adequate endogenous epo production and is mainly caused 
by a defective iron supply for erythropoiesis. IV iron saccha- 
rate appears to be an effective treatment for SoJCA patients 
with severe microcytic anemia, especially for those showing 
elevated serum TfR levels. Individuals with persistent micro- 
cytic anemia unresponsive to oral iron should be considered 
for such treatment. 
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